Oncorus Inc is a biotechnology business based in the US. Oncorus shares (ONCR) are listed on the NASDAQ and all prices are listed in US Dollars. Oncorus employs 56 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Oncorus
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ONCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Oncorus stock price (NASDAQ: ONCR)Use our graph to track the performance of ONCR stocks over time.
Oncorus shares at a glance
|Latest market close||$9.83|
|52-week range||$8.75 - $37.86|
|50-day moving average||$9.68|
|200-day moving average||$13.08|
|Wall St. target price||$37.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.46|
Buy Oncorus shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Oncorus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Oncorus price performance over time
|1 week (2021-10-14)||2.29%|
|1 month (2021-09-22)||3.04%|
|3 months (2021-07-22)||-25.87%|
|6 months (2021-04-22)||-31.93%|
|1 year (2020-10-21)||-34.47%|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-24.2%|
|Return on equity TTM||-62.94%|
|Market capitalisation||$246.9 million|
TTM: trailing 12 months
Shorting Oncorus shares
There are currently 687,961 Oncorus shares held short by investors – that's known as Oncorus's "short interest". This figure is 2.5% up from 671,076 last month.
There are a few different ways that this level of interest in shorting Oncorus shares can be evaluated.
Oncorus's "short interest ratio" (SIR)
Oncorus's "short interest ratio" (SIR) is the quantity of Oncorus shares currently shorted divided by the average quantity of Oncorus shares traded daily (recently around 90640.447957839). Oncorus's SIR currently stands at 7.59. In other words for every 100,000 Oncorus shares traded daily on the market, roughly 7590 shares are currently held short.
To gain some more context, you can compare Oncorus's short interest ratio against those of similar companies.
However Oncorus's short interest can also be evaluated against the total number of Oncorus shares, or, against the total number of tradable Oncorus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncorus's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oncorus shares in existence, roughly 30 shares are currently held short) or 0.0638% of the tradable shares (for every 100,000 tradable Oncorus shares, roughly 64 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Oncorus.
Find out more about how you can short Oncorus stock.
Oncorus share dividends
We're not expecting Oncorus to pay a dividend over the next 12 months.
Oncorus, Inc. , a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus in the news
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Oncorus to Present Initial Data from its Ongoing Phase 1 Clinical Trial of ONCR-177 at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Frequently asked questionsWhat percentage of Oncorus is owned by insiders or institutions?
Currently 2.397% of Oncorus shares are held by insiders and 79.355% by institutions. How many people work for Oncorus?
Latest data suggests 56 work at Oncorus. When does the fiscal year end for Oncorus?
Oncorus's fiscal year ends in December. Where is Oncorus based?
Oncorus's address is: 50 Hampshire Street, Cambridge, MA, United States, 02139 What is Oncorus's ISIN number?
Oncorus's international securities identification number is: US68236R1032
More guides on Finder
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Ask an Expert